Literature DB >> 21233507

Clinical significance of microbial infection and adaptation in cystic fibrosis.

Alan R Hauser1, Manu Jain, Maskit Bar-Meir, Susanna A McColley.   

Abstract

A select group of microorganisms inhabit the airways of individuals with cystic fibrosis. Once established within the pulmonary environment in these patients, many of these microbes adapt by altering aspects of their structure and physiology. Some of these microbes and adaptations are associated with more rapid deterioration in lung function and overall clinical status, whereas others appear to have little effect. Here we review current evidence supporting or refuting a role for the different microbes and their adaptations in contributing to poor clinical outcomes in cystic fibrosis.

Entities:  

Mesh:

Year:  2011        PMID: 21233507      PMCID: PMC3021203          DOI: 10.1128/CMR.00036-10

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  667 in total

1.  'Cepacia syndrome' with Burkholderia multivorans, 9 years after initial colonization.

Authors:  L Blackburn; K Brownlee; S Conway; M Denton
Journal:  J Cyst Fibros       Date:  2004-06       Impact factor: 5.482

2.  Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.

Authors:  G Taccetti; S Campana; F Festini; M Mascherini; G Döring
Journal:  Eur Respir J       Date:  2005-09       Impact factor: 16.671

3.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

4.  Quorum-sensing-deficient (lasR) mutants emerge at high frequency from a Pseudomonas aeruginosa mutS strain.

Authors:  Adela M Luján; Alejandro J Moyano; Ignacio Segura; Carlos E Argaraña; Andrea M Smania
Journal:  Microbiology       Date:  2007-01       Impact factor: 2.777

5.  Expression and regulation of tumor necrosis factor in macrophages from cystic fibrosis patients.

Authors:  K D Pfeffer; T P Huecksteadt; J R Hoidal
Journal:  Am J Respir Cell Mol Biol       Date:  1993-11       Impact factor: 6.914

6.  Investigation of the algT operon sequence in mucoid and non-mucoid Pseudomonas aeruginosa isolates from 115 Scandinavian patients with cystic fibrosis and in 88 in vitro non-mucoid revertants.

Authors:  Oana Ciofu; Baoleri Lee; Marie Johannesson; Nils Olav Hermansen; Peter Meyer; Niels Høiby
Journal:  Microbiology       Date:  2008-01       Impact factor: 2.777

7.  Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.

Authors:  M Ballmann; P Rabsch; H von der Hardt
Journal:  Thorax       Date:  1998-09       Impact factor: 9.139

8.  Effects of human neutrophil elastase and Pseudomonas aeruginosa proteinases on human respiratory epithelium.

Authors:  R Amitani; R Wilson; A Rutman; R Read; C Ward; D Burnett; R A Stockley; P J Cole
Journal:  Am J Respir Cell Mol Biol       Date:  1991-01       Impact factor: 6.914

Review 9.  Therapies aimed at airway inflammation in cystic fibrosis.

Authors:  M W Konstan
Journal:  Clin Chest Med       Date:  1998-09       Impact factor: 2.878

Review 10.  Viral respiratory infections in cystic fibrosis.

Authors:  Bart E van Ewijk; Marieke M van der Zalm; Tom F W Wolfs; Cornelis K van der Ent
Journal:  J Cyst Fibros       Date:  2005-08       Impact factor: 5.482

View more
  162 in total

1.  Ubiquitin and ubiquitin-modified proteins activate the Pseudomonas aeruginosa T3SS cytotoxin, ExoU.

Authors:  David M Anderson; Katherine M Schmalzer; Hiromi Sato; Monika Casey; Scott S Terhune; Arthur L Haas; Jimmy B Feix; Dara W Frank
Journal:  Mol Microbiol       Date:  2011-11-21       Impact factor: 3.501

Review 2.  Innate immune responses to Pseudomonas aeruginosa infection.

Authors:  Elise G Lavoie; Tamding Wangdi; Barbara I Kazmierczak
Journal:  Microbes Infect       Date:  2011-08-02       Impact factor: 2.700

3.  A Robust CRISPR Interference Gene Repression System in Pseudomonas.

Authors:  Sue Zanne Tan; Christopher R Reisch; Kristala L J Prather
Journal:  J Bacteriol       Date:  2018-03-12       Impact factor: 3.490

4.  Identification of the major ubiquitin-binding domain of the Pseudomonas aeruginosa ExoU A2 phospholipase.

Authors:  David M Anderson; Jimmy B Feix; Andrew L Monroe; Francis C Peterson; Brian F Volkman; Arthur L Haas; Dara W Frank
Journal:  J Biol Chem       Date:  2013-08-01       Impact factor: 5.157

5.  Chronic Airway Colonization by Achromobacter xylosoxidans in Cystic Fibrosis Patients Is Not Sustained by Their Domestic Environment.

Authors:  Chloé Dupont; Estelle Jumas-Bilak; Clara Doisy; Fabien Aujoulat; Raphaël Chiron; Hélène Marchandin
Journal:  Appl Environ Microbiol       Date:  2018-11-15       Impact factor: 4.792

6.  Achromobacter xylosoxidans: characterization of strains in Brazilian cystic fibrosis patients.

Authors:  Rosana H V Pereira; Ana Paula Carvalho-Assef; Rodolpho M Albano; Tania W Folescu; Marcia C M F Jones; Robson S Leão; Elizabeth A Marques
Journal:  J Clin Microbiol       Date:  2011-08-17       Impact factor: 5.948

Review 7.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 8.  Interplay Between Antibiotic Resistance and Virulence During Disease Promoted by Multidrug-Resistant Bacteria.

Authors:  Edward Geisinger; Ralph R Isberg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

9.  Evolutionary genomics of epidemic and nonepidemic strains of Pseudomonas aeruginosa.

Authors:  Jeremy R Dettman; Nicolas Rodrigue; Shawn D Aaron; Rees Kassen
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-09       Impact factor: 11.205

10.  Pseudomonas aeruginosa in vitro phenotypes distinguish cystic fibrosis infection stages and outcomes.

Authors:  Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman
Journal:  Am J Respir Crit Care Med       Date:  2014-08-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.